In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, a drug for schizophrenia that it thinks could have a clear side ...

The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics. Cerevel Therapeutics drug tavapadon met the main and ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?